Efficacy of 3D conformal thoracic radiotherapy for extensive‑stage small‑cell lung cancer: A retrospective study

Luan,Zupeng; Wang,Zhiwu; Huang,Wei; Zhang,Jian; Dong,Wei; Zhang,Wei; Li,Baosheng; Zhou,Tao; Li,Hongsheng; Zhang,Zicheng; Wang,Zhongtang; Sun,Hongfu; Yi,Yan

doi:10.3892/etm.2015.2526

Efficacy of 3D conformal thoracic radiotherapy for extensive‑stage small‑cell lung cancer: A retrospective study

Authors:
- Zupeng Luan
- Zhiwu Wang
- Wei Huang
- Jian Zhang
- Wei Dong
- Wei Zhang
- Baosheng Li
- Tao Zhou
- Hongsheng Li
- Zicheng Zhang
- Zhongtang Wang
- Hongfu Sun
- Yan Yi
View Affiliations

Affiliations: Department of Radiation Oncology, Cancer Hospital, Tianjin Medical University, National Clinical Research Center for Cancer, Key Laboratory if Cancer Prevention and Therapy, Tianjin 300060, P.R. China, Department of Radiation Oncology, Shandong Cancer Hospital, Shandong Academy of Medical Sciences, Jinan, Shandong 250117, P.R. China, Department of Radiation Oncology, Jinan Third People's Hospital, Jinan, Shandong 250101, P.R. China
Published online on: May 27, 2015 https://doi.org/10.3892/etm.2015.2526
Pages: 671-678

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to evaluate the effect of 3‑dimensional conformal thoracic radiotherapy (TRT) on extensive‑stage small‑cell lung cancer (ES‑SCLC). A total of 165 patients with ES‑SCLC were enrolled in the present study, including 82 patients receiving chemotherapy combined with TRT (the ChT/TRT group) and 83 patients receiving chemotherapy alone (the ChT group). The overall survival (OS) and progression‑free survival (PFS) rates were compared between the ChT/TRT and ChT groups, and the prognostic factors for OS rate were identified. It was found that the patients had a median OS time of 15 months, and 2‑ and 5‑year OS rates of 31.5 and 2.4%, respectively. The 2‑ and 5‑year OS rates were 35.3 and 2.4% in the ChT/TRT group, and 14.5 and 2.4% in the ChT group, respectively (P<0.05). The 1‑ and 2‑year PFS rates were 35.4 and 6.0% in the ChT/TRT group, and 20.5 and 6.0% in the ChT group, respectively (P<0.05). The median PFS was 11 months in the 20 patients receiving TRT at 45 Gy/30 fractions twice daily, and 9 months in the 22 patients receiving TRT at 60 Gy/30 fractions daily (P=0.043). Multivariate analysis revealed that receiving ≥4 cycles of chemotherapy (P=0.001) and TRT (P=0.008) were favorable prognostic factors for OS. It was concluded that the addition of TRT improves the OS and PFS rates of patients with ES‑SCLC, and TRT administration at 45 Gy/30 fractions twice daily is feasible and tolerable for the treatment of ES‑SCLC. Thus, TRT and receiving ≥4 cycles of chemotherapy are independent, favorable prognostic factors for OS in patients with ES‑SCLC.

View Figures

View References

1	Herbst RS, Heymach JV and Lippman SM: Lung cancer. N Engl J Med. 359:1367–1380. 2008. View Article : Google Scholar : PubMed/NCBI
2	van Meerbeeck JP, Fennell DA and De Ruysscher DK: Small-cell lung cancer. Lancet. 378:1741–1755. 2011. View Article : Google Scholar : PubMed/NCBI
3	Simon GR and Wagner HAmerican College of Chest Physicians: Small cell lung cancer. Chest. 123 (Suppl):259S–271S. 2003. View Article : Google Scholar : PubMed/NCBI
4	Jett JR, Schild SE, Kesler KA and Kalemkerian GP: Treatment of small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 143 (5 Suppl):e400S–e419S. 2013. View Article : Google Scholar : PubMed/NCBI
5	Zhu H, Zhou Z, Wang Y, et al: Thoracic radiation therapy improves the overall survival of patients with extensive-stage small cell lung cancer with distant metastasis. Cancer. 117:5423–5431. 2011. View Article : Google Scholar : PubMed/NCBI
6	Yee D, Butts C, Reiman A, et al: Clinical trial of post-chemotherapy consolidation thoracic radiotherapy for extensive-stage small cell lung cancer. Radiother Oncol. 102:234–238. 2012. View Article : Google Scholar : PubMed/NCBI
7	Pignon JP, Arriagada R, Ihde DC, Johnson DH, Perry MC, Souhami RL, et al: A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med. 327:1618–1624. 1992. View Article : Google Scholar : PubMed/NCBI
8	Warde P and Payne D: Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J Clin Oncol. 10:890–895. 1992.PubMed/NCBI
9	Takada M, Fukuoka M, Kawahara M, et al: Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: Results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol. 20:3054–3060. 2002. View Article : Google Scholar : PubMed/NCBI
10	Simon GR and Turrisi AAmerican College of Chest Physicians: Management of small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 132 (3 Suppl):324–339. 2007. View Article : Google Scholar
11	National Comprehensive Cancer Network, . Prostate cancer. NCCN Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2:224–248. 2004.PubMed/NCBI
12	Faivre-Finn C, Lorigan P, West C and Thatcher N: Thoracic radiation therapy for limited-stage small-cell lung cancer: Unanswered questions. Clin Lung Cancer. 7:23–29. 2005. View Article : Google Scholar : PubMed/NCBI
13	Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar : PubMed/NCBI
14	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
15	Hoffman PC, Mauer AM and Vokes EE: Lung cancer. Lancet. 355:479–485. 2000. View Article : Google Scholar : PubMed/NCBI
16	Samson DJ, Seidenfeld J, Simon GR, et al: Evidence for management of small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 132 (3 Suppl):314S–323S. 2007. View Article : Google Scholar : PubMed/NCBI
17	Cooper S and Spiro SG: Small cell lung cancer: treatment review. Respirology. 11:241–248. 2006. View Article : Google Scholar : PubMed/NCBI
18	Kallianos A, Rapti A, Zarogoulidis P, Tsakiridis K, Mpakas A, Katsikogiannis N, et al: Therapeutic procedure in small cell lung cancer. J Thorac Dis. 5 (Suppl 4):S420–S424. 2013.PubMed/NCBI
19	Ganti AK, West WW and Zhen W: Current concepts in the management of small cell lung cancer. Indian J Med Res. 137:1043–1051. 2013.PubMed/NCBI
20	Califano R, Abidin AZ, Peck R, Faivre-Finn C and Lorigan P: Management of small cell lung cancer: recent developments for optimal care. Drugs. 72:471–490. 2012. View Article : Google Scholar : PubMed/NCBI
21	Simon M, Argiris A and Murren JR: Progress in the therapy of small cell lung cancer. Crit Rev Oncol Hematol. 49:119–133. 2004. View Article : Google Scholar : PubMed/NCBI
22	National Comprehensive Cancer Network, . NCCN Clinical Practice Guidelines in Oncology. Small Cell Lung Cancer. v.2:2011 https://www.nccn.org/Accessed. May 21–2011
23	Früh M, De Ruysscher D, Popat S, Crinò L, Peters S and Felip EESMO Guidelines Working Group: Small-cell lung cancer (SCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 24 (Suppl 6):vi99–vi105. 2013. View Article : Google Scholar : PubMed/NCBI
24	Noda K, Nishiwaki Y, Kawahara M, et al: Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med. 346:85–91. 2002. View Article : Google Scholar : PubMed/NCBI
25	Hanna N, Bunn PA Jr, Langer C, et al: Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol. 24:2038–2043. 2006. View Article : Google Scholar : PubMed/NCBI
26	Natale RB, Lara PN, Chansky K, Crowley JJ, Jett JR, Carleton JE, et al: S0124: A randomized phase III trial comparing irinotecan/cisplatin (IP) with etoposide/cisplatin (EP) in patients (pts) with previously untreated extensive stage small cell lung cancer (E-SCLC). J Clin Oncol. 26 (Suppl):7512–2008
27	Toy E, Macbeth F, Coles B, Melville and Eastwood A: Palliative thoracic radiotherapy for non-small-cell lung cancer: A systematic review. Am J Clin Oncol. 26:112–120. 2003. View Article : Google Scholar : PubMed/NCBI
28	Jeremic B, Shibamoto Y, Nikolic N, et al: Role of radiation therapy in the combined-modality treatment of patients with extensive disease small-cell lung cancer: A randomized study. J Clin Oncol. 17:2092–2099. 1999.PubMed/NCBI
29	Turrisi AT III, Kim K, Blum R, Sause WT, Livingston RB, Komaki R, et al: Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med. 340:265–271. 1999. View Article : Google Scholar : PubMed/NCBI
30	Watkins JM, Fortney JA, Wahlquist AE, Shirai K, Garrett-Mayer E, Aguero EG, et al: Once-daily radiotherapy to > or =59.4 Gy versus twice-daily radiotherapy to > or =45.0 Gy with concurrent chemotherapy for limited-stage small-cell lung cancer: a comparative analysis of toxicities and outcomes. Jpn J Radiol. 28:340–348. 2010. View Article : Google Scholar : PubMed/NCBI
31	Schild SE, Bonner JA, Shanahan TG, et al: Long-term results of a phase III trial comparing once-daily radiotherapy with twice-daily radiotherapy in limited-stage small-cell lung cancer. Int J Radiat Oncol Biol Phys. 59:943–951. 2004. View Article : Google Scholar : PubMed/NCBI
32	Giuliani ME, Atallah S, Sun A, et al: Clinical outcomes of extensive stage small cell lung carcinoma patients treated with consolidative thoracic radiotherapy. Clin Lung Cancer. 12:375–379. 2011. View Article : Google Scholar : PubMed/NCBI
33	Schiller JH, Adak S, Cella D, et al: Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593 - a phase III trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 19:2114–2122. 2001.PubMed/NCBI
34	Slotman B, Faivre-Finn C, Kramer G, Rankin E, Snee M, Hatton M, et al: Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med. 357:664–672. 2007. View Article : Google Scholar : PubMed/NCBI
35	Roeder F, Friedrich J, Timke C, Kappes J, Huber P, Krempien R, Debus J and Bischof M: Correlation of patient-related factors and dose-volume histogram parameters with the onset of radiation pneumonitis in patients with small cell lung cancer. Strahlenther Onkol. 186:149–156. 2010. View Article : Google Scholar : PubMed/NCBI